Phase 1 study of dry eye solution launched

Article

Novaliq GmbH is launching a Phase 1 study of its 0.05% clear cyclosporine solution (CyclASol) following European and US patent approval of the solution for the treatment of dry eye syndrome.

Novaliq GmbH is launching a Phase 1 study of its 0.05% clear cyclosporine solution (CyclASol) following European and US patent approval of the solution for the treatment of dry eye syndrome.

CyclASol was developed from EyeSol, Novaliq's broad range semi-fluorinated alkane (SFA) drug delivery platform. Novaliq says the platform offers significant benefits for delivery of ophthalmological drugs, primarily by enhancing the therapeutic effect of poorly soluble drugs.

According to Novaliq, CyclASol has demonstrated long-term stability and wettability, pharmacokinetics, and biocompatibility superior to that of conventional emulsion formulations of cyclosporine. CyclASol is available in multidose and preservative-free bottles.

"We are pleased to receive the US and European patent and to announce the start of a Phase 1 CyclASol study," Bernhard Günther, CEO of Novaliq GmbH, said. "These are both significant new milestones for Novaliq as we build our innovative drug delivery portfolio."

"We congratulate Novaliq on obtaining patent approval for CyclASol and the start of their clinical trials," said Mathias Hothum, managing director of investment company Dievini Hopp BioTech Holding GmbH & Co. KG. "We are pleased to support Novaliq as it pioneers new topical ocular drug delivery technology. We endorse Novaliq's strategy to establish a portfolio of consumer and prescription product portfolios within ophthalmology."

For more information, visit www.novaliq.de or e-mail: info@novaliq.de.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.